The family of nuclear peroxisome proliferator-activated receptors (PPAR伪, PPAR尾/未, and PPAR纬) is a set of ligand-activated transcription factors that regulate different functions in the body. Whereas activation of PPAR伪 is known to reduce the levels of circulating triglycerides and regulate energy homeostasis, the activation of PPAR纬 brings about insulin sensitization and increases the metabolism of glucose. On the other hand, PPAR尾 when activated increases the metabolism of fatty acids. Further, these PPARs have been claimed to be utilized in various metabolic, neurological, and inflammatory diseases, neurodegenerative disorders, fertility or reproduction, pain, and obesity. A series of different heterocyclic scaffolds have been synthesized and evaluated for their ability to act as PPAR agonists. This review is a compilation of efforts on the part of medicinal chemists around the world to find novel compounds that may act as PPAR ligands along with patents in regards to PPAR ligands. The structure-activity relationship, as well as docking studies, have been documented to better understand the mechanistic investigations of various compounds, which will eventually aid in the design and development of new PPAR ligands. From the results of the structural activity relationship through the pharmacological and in silico evaluation the potency of heterocycles as PPAR ligands can be described in terms of their hydrogen bonding, hydrophobic interactions, and other interactions with PPAR.
Browse by Audience
Skip to content